Corvus Pharmaceuticals (CRVS) Operating Leases (2022 - 2025)
Historic Operating Leases for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $632000.0.
- Corvus Pharmaceuticals' Operating Leases rose 7853.11% to $632000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $632000.0, marking a year-over-year increase of 7853.11%. This contributed to the annual value of $937000.0 for FY2024, which is 3180.49% down from last year.
- Corvus Pharmaceuticals' Operating Leases amounted to $632000.0 in Q3 2025, which was up 7853.11% from $728000.0 recorded in Q2 2025.
- In the past 5 years, Corvus Pharmaceuticals' Operating Leases ranged from a high of $2.3 million in Q1 2022 and a low of $354000.0 during Q3 2023
- Over the past 4 years, Corvus Pharmaceuticals' median Operating Leases value was $937000.0 (recorded in 2024), while the average stood at $1.1 million.
- Per our database at Business Quant, Corvus Pharmaceuticals' Operating Leases plummeted by 7904.09% in 2023 and then skyrocketed by 7853.11% in 2025.
- Quarter analysis of 4 years shows Corvus Pharmaceuticals' Operating Leases stood at $1.4 million in 2022, then increased by 0.07% to $1.4 million in 2023, then plummeted by 31.8% to $937000.0 in 2024, then tumbled by 32.55% to $632000.0 in 2025.
- Its last three reported values are $632000.0 in Q3 2025, $728000.0 for Q2 2025, and $834000.0 during Q1 2025.